Table 2.

Schedule of assessments

Procedure/ Point in Time	Screening	Treatment				Post- Treatment
	Inclusion	C1D1	Each cycle (q2w ± 3 days)	Every second cycle (q4w ± 3 days)	EOT	Safety FU-1*	Safety FU-2**	FU (q12w ± 14 days)
Central review – ILD exclusion#	(x)
Informed consent, eligibility criteria, demographics, medical and disease history	x
Prior and Concomitant Medication Review	x	x	x		x
Allocation/Randomization	x
Vital Signs, O2 Saturation, and Weight	x	x	x		x	x	x
ECOG Performance Status	x	x	x		x
Pregnancy Test, CBC with Differential, Serum Chemistry Panel, Thyroid function test	x	x	x		x
Urinalysis	x	Whenever clinically indicated
12-lead ECG	x	Whenever clinically indicated
Pulmonary function tests	x	xa		together with staging	x	x	x
AEs	x	x	x		x	x	x	x
Full Physical Examination	x
Directed Physical Examination		x	x		x	x	x
FACT-L questionnaire	x	x		x	x	x	x	(x)
Tumor Imaging	x	(xb)		(xc)	(xd)			(xd)
Tissue	x	Optional: Re-Biopsy at time of progression
Blood and stool	x	(xe)	x	x	x
Atezolizumab administration		x	x
Radiotherapy (Arm Af)		x

^#: A sponsor-independent adjudication committee was established to exclude interstitial lung disease (ILD) [Excl. criterion 5] in all pre-screened patients prior to study inclusion. All study sites are encouraged to provide tumor imaging in pseudonymize form during the (pre-)screening phase for the central review process

*: The regular 30-day full safety follow-up period (FU-1) begins on the day after the EOT visit and lasts approximately 30 days. The FU-1 visit occurs at or near the end of the 30-day safety follow-up period (±7 days)

**: The regular 90-day full safety follow-up period (FU-2) begins on the day after the EOT visit and lasts approximately 90 days. The FU-2 visit occurs at or near the end of the 90-day safety follow-up period (±7 days)

^a: To be performed on C1D1 if in accordance with local standard

^b: Chest X-ray to be performed on cycle 1 if in accordance with local standard

^c: First on-study imaging to be performed 6 weeks (± 7 days) after baseline imaging. Further on-study imaging to be performed Q6W (42 days ±7 days) for the first 36 weeks, and every 9 weeks (±7 days) thereafter until occurrence of disease progression, according to the standard of care

^d: Only applicable if EOT not according to already detected disease progression

^e: Biomarker sample to be taken prior to first study drug medication or before first administration of thoracic radiotherapy for arm A, either during screening or C1D1 visit

^f: Patients in arm A receive thoracic radiotherapy with a dose fractionation of 10 × 3 Gy (30 Gy) within 2 weeks (+ 7 days) in combination with atezolizumab treatment. Thoracic radiotherapy to be started within 7 weeks after C4D1 of induction therapy